While no FDA-approved indication exists for GLP-1 medications in lymphedema, emerging interest focuses on whether weight loss achieved through these agents might benefit obese patients with this condition
The triple therapy of metformin, a DPP-4 inhibitor and a SGLT-2 inhibitor has a very low treatment related hypoglycaemia risk, leads to a further, almost additive reduction of glycaemic parameters, a body weight loss in the same range as with a mono- or dual therapy with a SGLT-2 inhibitor and also to the expected SGLT-2 inhibitor induced reduction of blood pressure
Because they work so hard, they naturally produce a lot of metabolic byproducts (free radicals)
Probiotics: These beneficial bacteria may help restore the natural balance of your cat's gut microbiome
Always consult with a healthcare provider before starting supplementation, especially if you have underlying health conditions or are pregnant
Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties